

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
EARLY TERMINATION OF PROMOTIONAL SERVICE AGREEMENT

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated July 26, 2020 (the “**Announcement**”) in relation to the promotional service agreement (the “**Agreement**”) entered into by and between the Company and Pfizer Investment Co., Ltd. (輝瑞投資有限公司) (“**Pfizer**”), pursuant to which the Company authorized Pfizer to exclusively promote the Groups A, C, Y and W135 meningococcal conjugate vaccine of the Company (the “**MCV4**”, trade name: Menhycia) in the PRC after obtaining NDA approval. Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

On June 4, 2022, the Company and Pfizer entered into a termination agreement upon friendly negotiation, pursuant to which the parties thereto agreed to terminate the Agreement and the exclusive promotion authorization with immediate effect. The Company and Pfizer will work on the outstanding matters arising from or otherwise in relation to the termination of the cooperation under the Agreement.

The Company has established the centre of commercialization with comprehensive system. The Company's own commercialization team will help the Company to formulate and execute domestic and overseas promotion strategies and marketing operation for MCV4. The Company believes that the commercialization of MCV4 will narrow the gap between China and developed countries and fill the vacancy of China's lack of high-end vaccine in this field, and therefore has a bright future in the PRC market.

The Company is of the view that its decision to terminate the Agreement will not cause any material adverse impact on the business, operation or financial condition of the Group.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 5, 2022

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.